Senate Health Care
Senate Health Care
Sen. Susan Collins, R-Maine, asks a question during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen, center, testifies during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
Sen. Bill Cassidy, R-La., asks a question during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen, testifies during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen, testifies during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
Sen. Bernie Sanders, I-Vt., asks a question during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen, testifies during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen, testifies during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Senate Health Care
President and chief executive officer, Novo Nordisk, Lars Fruergaard Jørgensen, testifies during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)
Абонирайте се
Влезте във Вашата БТА
Избиране на снимки
Моля потвърдете избраните снимки. Това действие не е свързано с плащане. Ако продължите, избраните снимки ще бъдат извадени от баланса на вашите активни абонаментни пакети.
Изтегляне на снимка
Моля потвърдете изтеглянето на снимката/ите
Sen. Susan Collins, R-Maine, asks a question during a Senate Health, Education, Labor, and Pensions hearing to examine Novo Nordisk's high prices for Ozempic and Wegovy for patients with diabetes and obesity on Capitol Hill, Tuesday, Sept. 24, 2024, in Washington. (AP Photo/Mariam Zuhaib)